Compass Pathways jumps as depression treatment study meets main goal

COMPASS Pathways

17/02/2026 18:29

Updates

** Shares of Compass Pathways CMPS.O rise as much as 51.46% to over one-year high of $8.80

** Stock set for its biggest percentage jump, if gains hold

** Co says its experimental therapy, COMP360, helped people with treatment‑resistant depression, a hard‑to‑treat form of the illness

** Says two late‑stage trials showed higher doses of COMP360 improved symptoms more than a low dose or placebo

** Says patients given two doses, three weeks apart, showed meaningful six‑week improvement, with benefits seen as early as the next day

** "With two positive late-stage studies and robust durability data, Compass is on track to be the first psychedelic approved by the FDA, likely in 2027" - Cantor analyst Josh Schimmer

** Side effects such as headache, nausea and anxiety were mostly mild or moderate - CMPS

** Co aims to file for U.S. FDA approval later this year

** CMPS rose ~83% in 2025

(Reporting by Sahil Pandey in Bengaluru)

((Sahil.Pandey@thomsonreuters.com))